metaEvidence - overview


DCR
es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)
es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)
versus lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
	trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel vs. lapatinib plus epirubicin and cyclophosphamide followed by docetaxel	1	-
la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)
versus trastuzumab
	pertuzumab plus trastuzumab vs. trastuzumab	1	-
versus trastuzumab plus chemotherapy
	trastuzumab plus endocrine therapy vs. trastuzumab plus chemotherapy	1	-
versus trastuzumab plus docetaxel
	pertuzumab plus trastuzumab plus docetaxel vs. trastuzumab plus docetaxel	2	-
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus lapatinib
	lapatinib plus trastuzumab vs. lapatinib	1	-
versus lapatinib plus capecitabine
	neratinib plus capecitabine vs. lapatinib plus capecitabine	2	-
versus placebo
	neratinib vs. placebo	1	-
versus trastuzumab plus capecitabine
	lapatinib plus capecitabine vs. trastuzumab plus capecitabine	1
	tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine	2	-
versus trastuzumab plus vinorelbine
	afatinib plus vinorelbine vs. trastuzumab plus vinorelbine	1	-